Dyne Therapeutics (DYN) Financials: Revenue & Earnings

DYN price $16.84 -0.10 -0.61%

Ticker
DYN
Price
$16.84
Change
-0.10 -0.61%
Market cap ?
$3.14B
P/E ?
-4.92
Forward P/E ?
34.46
Dividend yield ?
0.00%
Beta ?
1.12
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
69
Value
55
Quality
53
Growth
100

Stocklytics score rationale: value 55, quality 53, growth 100.

Financials

2016201720182019202020212022202320242025
136600000050600000000000000

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and…

Fair value

DYN fair value $14.94. Price $16.84. Price is 13% above fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 32.37M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 10.46% (beta 1.1). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 186.75M. Net debt -873.09M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare DYN

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-04—-0.91——
2026-07-30-1.08-0.75——
2026-05-11-0.73-0.77——
2026-03-02-0.76-0.74——
2025-11-05-0.76-0.81——
2025-07-28-0.97-0.99——
2025-05-08-1.05-0.88——
2025-02-27-0.88-0.92——
2024-11-12-0.96-0.71——
2024-08-12-0.70-0.72——
2024-05-02-0.81-0.81—1.67M
2024-03-05-1.09-0.923.79M—
2023-10-30-0.99-0.86——
2023-08-03-1.08-0.81——
2023-05-11-0.78-0.77——
2023-03-02-0.74-0.84——
2022-11-03-0.80-0.95——
2022-08-04-1.01-0.79——
2022-05-02-0.69-0.88——
2022-03-10-1.00-0.99——
2021-11-04-0.83-0.65——
2021-08-05-0.58-0.55——
2021-05-06-0.50-0.60——
2021-03-04-0.64-0.38——
2020-11-05-2.01-0.87——
2020-09-17-0.62———
2020-06-30-0.22———
2019-12-31-0.42———
2019-09-30-0.46———
2019-06-30-0.76———
2019-03-31-0.76———
2018-02-22-8.71—470.00M—
2017-11-01-0.82—182.00M—
2017-08-04-1.83—181.00M—
2017-05-053.69—175.00M—
2017-02-24-1.41—791.00M—
2016-11-02-1.98—241.00M—
2016-08-04-6.81—166.00M—
2016-05-04-0.08—168.00M—
2016-02-25-1.06—217.00M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-20Kerr DouglasBuy8.00K——
2026-10-20Kerr DouglasBuy12.00K$16.27195.24K
2026-10-02Posner Brian SBuy2.50K$16.0040.00K
2026-09-08Friedl-Naderer JohannaSell185$18.883.49K
2026-09-08Kerr DouglasSell1.29K$18.8824.36K
2026-09-08Cox JohnSell5.66K$18.88106.82K
2026-09-04Friedl-Naderer JohannaSell900$24.3521.91K
2026-09-04Kerr DouglasSell3.75K$24.3591.19K
2026-08-14Rhodes Jason PSell1.36M$25.0033.99M
2026-08-14Rhodes Jason PSell478.38K$25.0011.96M
2026-08-14Rhodes Jason PSell322.46K$25.008.06M
2026-08-13Rhodes Jason PSell268.35K$26.207.03M
2026-08-13Rhodes Jason PSell94.42K$26.202.47M
2026-08-13Rhodes Jason PSell63.64K$26.201.67M
2026-08-13Friedl-Naderer JohannaSell226$26.285.94K
2026-08-13Kerr DouglasSell1.56K$26.2840.89K
2026-08-13Cox JohnSell4.99K$26.28131.03K
2026-08-13Lucera ErickSell1.80K$26.2847.23K
2026-07-27Kersten DirkSell256.07K$25.506.53M
2026-07-27Kersten DirkSell5.39K$26.04140.32K
2026-07-07Rhodes Jason PSell124.38K$23.172.88M
2026-07-07Rhodes Jason PSell29.59K$23.62698.84K
2026-07-07Rhodes Jason PSell62.54K$23.171.45M
2026-07-07Rhodes Jason PSell14.84K$23.62350.62K
2026-07-07Rhodes Jason PSell49.19K$23.171.14M
2026-07-07Rhodes Jason PSell11.66K$23.62275.53K
2026-07-07Rhodes Jason PSell5.00K$23.61118.05K
2026-07-06Rhodes Jason PSell253.04K$22.795.77M
2026-07-06Rhodes Jason PSell127.18K$22.792.90M
2026-07-06Rhodes Jason PSell100.02K$22.792.28M
2026-06-29Rhodes Jason PSell102.97K$21.142.18M
2026-06-29Rhodes Jason PSell51.76K$21.141.09M
2026-06-29Rhodes Jason PSell40.70K$21.14860.44K
2026-06-26Rhodes Jason PSell162.95K$21.283.47M
2026-06-26Rhodes Jason PSell81.90K$21.281.74M
2026-06-26Rhodes Jason PSell64.41K$21.281.37M
2026-06-25Lucera ErickSell2.36K$20.3748.11K
2026-06-25Rhodes Jason PSell12.70K$21.10267.95K
2026-06-25Rhodes Jason PSell6.38K$21.10134.66K
2026-06-25Rhodes Jason PSell5.02K$21.10105.90K
2026-06-24Rhodes Jason PSell50.53K$21.021.06M
2026-06-24Rhodes Jason PSell25.40K$21.02533.84K
2026-06-24Rhodes Jason PSell19.97K$21.02419.83K
2026-06-23Rhodes Jason PSell77.86K$21.131.65M
2026-06-23Rhodes Jason PSell39.13K$21.13826.84K
2026-06-23Rhodes Jason PSell30.77K$21.13650.25K
2026-06-23Kersten DirkSell71.63K$21.041.51M
2026-06-23Kersten DirkSell1.66K$21.4735.58K
2026-06-22Kersten DirkSell190.68K$20.573.92M
2026-06-22Greene Barry EBuy57.46K$20.871.20M
2026-06-22Greene Barry EOther0——
2026-06-18Kersten DirkSell46.90K$20.07941.37K
2026-06-17Kersten DirkSell37.45K$20.14754.32K
2026-06-16Kerr DouglasSell887$18.3316.26K
2026-06-16Friedl-Naderer JohannaSell145$18.332.66K
2026-06-16Cox JohnSell2.68K$18.3349.18K
2026-06-08Posner Brian SBuy2.00K$16.9433.88K
2026-06-05HURWITZ EDWARDBuy35.15K$17.04598.99K
2026-06-05Lubner David CharlesBuy35.15K$17.04598.99K
2026-06-05Rhodes Jason PBuy35.15K$17.04598.99K
2026-06-05Kersten DirkBuy35.15K$17.04598.99K
2026-06-05Incerti CarloBuy35.15K$17.04598.99K
2026-06-05Stehman-Breen CatherineBuy35.15K$17.04598.99K
2026-06-05Posner Brian SBuy35.15K$17.04598.99K
2026-06-03Posner Brian SBuy2.50K$17.4843.70K
2026-05-26Posner Brian SBuy2.00K$18.2136.42K
2026-05-20Posner Brian SBuy2.50K$17.1242.80K
2026-05-13Friedl-Naderer JohannaSell228$18.364.19K
2026-05-13Kerr DouglasSell1.56K$18.3628.72K
2026-05-13Lucera ErickSell1.45K$18.3626.59K
2026-05-13Cox JohnSell3.31K$18.3660.79K
2026-05-06Rhodes Jason PSell43.62K$18.18793.03K
2026-05-06Rhodes Jason PSell21.93K$18.18398.61K
2026-05-06Rhodes Jason PSell17.24K$18.18313.50K
2026-05-06Rhodes Jason PSell428$18.187.78K
2026-05-05Rhodes Jason PSell6.08K$18.03109.64K
2026-05-05Rhodes Jason PSell3.06K$18.0355.10K
2026-05-05Rhodes Jason PSell2.40K$18.0343.33K
2026-05-05Rhodes Jason PSell60$18.031.08K
2026-05-04Rhodes Jason PSell6.24K$18.00112.34K
2026-05-04Rhodes Jason PSell3.14K$18.0056.45K
2026-05-04Rhodes Jason PSell2.47K$18.0044.39K
2026-05-04Rhodes Jason PSell61$18.001.10K
2026-04-28Rhodes Jason PSell119.11K$18.382.19M
2026-04-28Rhodes Jason PSell52$19.00988
2026-04-28Rhodes Jason PSell59.87K$18.381.10M
2026-04-28Rhodes Jason PSell26$19.00494
2026-04-28Rhodes Jason PSell47.08K$18.38865.37K
2026-04-28Rhodes Jason PSell21$19.00399
2026-04-28Rhodes Jason PSell1.17K$18.3821.50K
2026-04-28Rhodes Jason PSell1$19.0019
2026-04-27Rhodes Jason PSell90.94K$18.151.65M
2026-04-27Rhodes Jason PSell45.71K$18.15829.62K
2026-04-27Rhodes Jason PSell35.95K$18.15652.44K
2026-04-27Rhodes Jason PSell894$18.1516.23K
2026-04-24Lubner David CharlesSell53.62K——
2026-04-24Rhodes Jason PSell72.31K$18.481.34M
2026-04-24Rhodes Jason PSell36.34K$18.48671.66K
2026-04-24Rhodes Jason PSell28.58K$18.48528.21K
2026-04-24Rhodes Jason PSell710$18.4813.12K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 254, holders +18 vs prior quarter. Ownership 116.23%.

HolderSharesChangeChange %Value
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.30.91M126.49K+0.41%686.56M
BLACKROCK, INC.12.40M704.46K+6.02%275.50M
JUPITER TOPCO LLC12.00M12.00MNew266.63M
FMR LLC11.21M2.30M+25.79%248.91M
STATE STREET CORP7.46M804.52K+12.09%165.65M
ORBIS ALLAN GRAY LTD7.01M244.31K+3.61%155.62M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC6.80M-2.33M-25.52%151.03M
VANGUARD CAPITAL MANAGEMENT LLC6.31M-94.10K-1.47%140.17M
TCG CROSSOVER MANAGEMENT, LLC4.62M00.00%102.50M
VANGUARD PORTFOLIO MANAGEMENT LLC4.05M-113.61K-2.73%89.92M
PRICE T ROWE ASSOCIATES INC /MD/3.94M1.61M+69.08%87.44M
FCPM III SERVICES B.V.3.85M-796.13K-17.14%85.47M
GEODE CAPITAL MANAGEMENT, LLC3.74M239.31K+6.83%83.16M
VESTAL POINT CAPITAL, LP3.38M-625.00K-15.62%74.96M
ORBIMED ADVISORS LLC3.24M317.80K+10.89%71.86M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.3.15M00.00%70.03M
ARMISTICE CAPITAL, LLC3.09M-87.88K-2.77%68.57M
JPMORGAN CHASE & CO3.15M-101.82K-3.13%67.15M
PERCEPTIVE ADVISORS LLC2.69M-1.98M-42.40%59.73M
LOGOS GLOBAL MANAGEMENT LP2.55M1.15M+82.14%56.64M
BANK OF AMERICA CORP /DE/2.23M790.09K+54.74%49.60M
VENROCK ADVISER, LLC2.17M00.00%48.28M
GOLDMAN SACHS GROUP INC2.16M434.08K+25.19%47.91M
SIREN, L.L.C.2.13M-100.00K-4.49%47.29M
FRANKLIN TEMPLETON INC2.03M21.74K+1.08%45.10M

Earnings and financials

Dyne Therapeutics, Inc. (DYN) trades at $16.84, with a market cap of $3.14B and a trailing P/E of -4.92. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
136600000050600000000000000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Dyne Therapeutics (DYN) Financials: Revenue & Earnings

DYN$16.84-0.10 -0.61%

$3.14B

Market Cap

-4.92

P/E

34.46

Forward P/E

69

Score

Price History